Lipid‑based nanoparticles for the therapeutic delivery of non‑coding RNAs in breast cancer (Review)
- Authors:
- Macrina B. Silva‑Cázares
- María Z. Saavedra‑Leos
- Euclides Jordan‑Alejandre
- Stephanie I. Nuñez‑Olvera
- Isaac Cómpean‑Martínez
- César López‑Camarillo
-
Affiliations: Institutional Doctorate in Engineering and Matherials Science, Autonomous University of San Luis Potosí, San Luis Potosí 78760, México, Oncogenomics Laboratory, Autonomous University of México City, México City 03100, México - Published online on: October 5, 2020 https://doi.org/10.3892/or.2020.7791
- Pages: 2353-2363
This article is mentioned in:
Abstract
Cavallo F, Giovanni C, Nanni P, Forni G and Lollini PL: 2011: The immune hallmarks of cancer. Cancer Immunol Immunother. 60:319–326. 2011. View Article : Google Scholar : PubMed/NCBI | |
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, et al: Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 124:2785–2800. 2018. View Article : Google Scholar : PubMed/NCBI | |
Breast Cancer Treatment|Treatment Options for Breast Cancer. | |
Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI | |
Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI | |
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
Yingchoncharoen P, Kalinowski DS and Des Richardson R: Lipid-based drug delivery systems in cancer therapy: What is available and what is yet to come. Pharmacol Rev. 68:701–787. 2016. View Article : Google Scholar : PubMed/NCBI | |
Mudshinge SR, Deore AB, Patil S and Bhalgat CM: Nanoparticles: Emerging carriers for drug delivery. Saudi Pharm J. 19:129–141. 2011. View Article : Google Scholar : PubMed/NCBI | |
Del Pozo-Rodríguez A, Solinís MÁ and Rodríguez-Gascón A: Applications of lipid nanoparticles in gene therapy. Eur J Pharm Biopharm. 109:184–193. 2016. View Article : Google Scholar : PubMed/NCBI | |
Hashemi M and Kalalinia F: Application of encapsulation technology in stem cell therapy. Life Sci. 143:139–146. 2015. View Article : Google Scholar : PubMed/NCBI | |
Aagaard L and Rossi JJ: RNAi therapeutics: Principles, prospects and challenges. Adv Drug Deliv Rev. 59:75–86. 2007. View Article : Google Scholar : PubMed/NCBI | |
Chen G, Wang Y, Xie R and Gong S: Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery. J Control Release. 259:105–114. 2017. View Article : Google Scholar : PubMed/NCBI | |
Deng X, Cao M, Zhang J, Hu K, Yin Z, Zhou Z, Xiao X, Yang Y, Sheng W, Wu Y and Zeng Y: Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials. 35:4333–4344. 2014. View Article : Google Scholar : PubMed/NCBI | |
Hogrefe RI, Lebedev AV, Zon G, Pirollo KF, Rait A, Zhou Q, Yu W and Chang EH: Chemically modified short interfering hybrids (siHYBRIDS): Nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids. 25:889–907. 2006. View Article : Google Scholar : PubMed/NCBI | |
Shu D, Li H, Shu Y, Xiong G, Carson WE III, Haque F, Xu R and Guo P: Systemic delivery of Anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano. 9:9731–9740. 2015. View Article : Google Scholar : PubMed/NCBI | |
Urban-Klein B, Werth S, Abuharbeid S, Czubayko F and Aigner A: RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12:461–466. 2005. View Article : Google Scholar : PubMed/NCBI | |
Yhee JY, Song S, Lee SJ, Park SG, Kim KS, Kim MG, Son S, Koo H, Kwon IC, Jeong JH, et al: Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance. J Control Release. 198:1–9. 2015. View Article : Google Scholar : PubMed/NCBI | |
Guo P, You JO, Yang J, Di J, Moses MA and Auguste DT: Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade. Mol Pharm. 11:755–765. 2014. View Article : Google Scholar : PubMed/NCBI | |
Reichmuth AM, Oberli MA, Jaklenec A, Langer R and Blankschtein D: mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 7:319–334. 2016. View Article : Google Scholar : PubMed/NCBI | |
de la Harpe K, Kondiah P, Choonara Y, Marimuthu T, du Toit L and Pillay V: The hemocompatibility of nanoparticles: A review of cell-nanoparticle interactions and hemostasis. Cells. 8:12092019. View Article : Google Scholar | |
Buzea C, Pacheco II and Robbie K: Nanomaterials and nanoparticles: Sources and toxicity. Biointerphases. 2:MR17–MR71. 2007. View Article : Google Scholar : PubMed/NCBI | |
Huang Y, Gao X and Chen J: Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy. Acta Pharm Sin B. 8:4–13. 2018. View Article : Google Scholar : PubMed/NCBI | |
Huynh A, Madu CO and Lu Y: siRNA: A promising new tool for future breast cancer therapy. Oncomedicine. 3:74–81. 2018. View Article : Google Scholar | |
Singh A, Trivedi P and Jain NK: Advances in siRNA delivery in cancer therapy. Artif Cells Nanomed Biotechnol. 46:274–283. 2018. View Article : Google Scholar : PubMed/NCBI | |
Hayward SL, Francis DM, Kholmatov P and Kidambi S: Targeted delivery of MicroRNA125a-5p by engineered lipid nanoparticles for the treatment of HER2 positive metastatic breast cancer. J Biomed Nanotechnol. 12:554–568. 2016. View Article : Google Scholar : PubMed/NCBI | |
Liu J, Meng T, Ming Y, Wen L, Cheng B, Liu N, Huang X, Hong Y, Yuan H and Hu F: MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell. Int J Nanomedicine. 11:6713–6725. 2016. View Article : Google Scholar : PubMed/NCBI | |
Wang X, Yu B, Wu Y, Lee RJ and Lee LJ: Efficient down-regulation of CDK4 by novel lipid nanoparticle-mediated siRNA delivery. Anticancer Res. 31:1619–1626. 2011.PubMed/NCBI | |
Tang J, Howard CB, Mahler SM, Thurecht KJ, Huang L and Xu ZP: Enhanced delivery of siRNA to triple negative breast cancer cells in vitro and in vivo through functionalizing lipid-coated calcium phosphate nanoparticles with dual target ligands. Nanoscale. 10:4258–4266. 2018. View Article : Google Scholar : PubMed/NCBI | |
Yu YH, Kim E, Park DE, Shim G, Lee S, Kim YB, Kim CW and Oh YK: Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur J Pharm Biopharm. 80:268–273. 2012. View Article : Google Scholar : PubMed/NCBI | |
Zheng ZM, Tang S and Tao M: Development of resistance to RNAi in mammalian cells. Ann NY Acad Sci. 1058:105–118. 2005. View Article : Google Scholar : PubMed/NCBI | |
Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI | |
Yang W, Lee DY and Ben-David Y: The roles of microRNAs in tumorigenesis and angiogenesis. Int J Physiol Pathophysiol Pharmacol. 3:140–155. 2011.PubMed/NCBI | |
Kwon T, Chandimali N, Huynh DL, Zhang JJ, Kim N, Bak Y, Yoon DY, Yu DY, Lee JC, Gera M, et al: BRM270 inhibits cancer stem cell maintenance via microRNA regulation in chemoresistant A549 lung adenocarcinoma cells. Cell Death Dis. 9:2442018. View Article : Google Scholar : PubMed/NCBI | |
Zhao M, Ang L, Huang J and Wang J: MicroRNAs regulate the epithelial-mesenchymal transition and influence breast cancer invasion and metastasis. Tumour Biol. 39:1010428317691682. 2017. View Article : Google Scholar | |
Barbarotto E and Calin GA: MicroRNAs and drug resistance. Drug Resistance Cancer Cells. 102:257–270 | |
Kim J, Yao F, Xiao Z, Sun Y and Ma L: MicroRNAs and metastasis: Small RNAs play big roles. Cancer Metastasis Rev. 37:5–15. 2018. View Article : Google Scholar : PubMed/NCBI | |
McGuire A, Brown JA and Kerin MJ: Metastatic breast cancer: The potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 34:145–155. 2015. View Article : Google Scholar : PubMed/NCBI | |
Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K and Croce CM: Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci USA. 109:3024–3029. 2012. View Article : Google Scholar : PubMed/NCBI | |
Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Ann Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI | |
Klinge CM: Non-coding RNAs in breast cancer: Intracellular and intercellular communication. Noncoding RNA. 4:402018. | |
Kanasty R, Dorkin JR, Vegas A and Anderson D: Delivery materials for siRNA therapeutics. Nat Materials. 12:967–977. 2013. View Article : Google Scholar : PubMed/NCBI | |
Majumder S and Jacob ST: Emerging role of microRNAs in drug-resistant breast cancer. Gene Expr. 15:141–151. 2011. View Article : Google Scholar : PubMed/NCBI | |
Papadaki C, Stratigos M, Markakis G, Spiliotaki M, Mastrostamatis G, Nikolaou C, Mavroudis D and Agelaki S: Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer. Breast Cancer Res. 20:722018. View Article : Google Scholar : PubMed/NCBI | |
Quan Y, Huang X and Quan X: Expression of miRNA-206 and miRNA-145 in breast cancer and correlation with prognosis. Oncol Lett. 16:6638–6642. 2018.PubMed/NCBI | |
Wang H, Peng R, Wang J, Qin Z and Xue L: Circulating microRNAs as potential cancer biomarkers: The advantage and disadvantage. Clinical Epigenetics. 10:592018. View Article : Google Scholar : PubMed/NCBI | |
Abdelrahim M, Safe S, Baker C and Abudayyeh A: RNAi and cancer: Implications and applications. J RNAi Gene Silencing. 2:136–145. 2006.PubMed/NCBI | |
Ewert KK, Zidovska A, Ahmad A, Bouxsein NF, Evans HM, McAllister CS, Samuel CE and Safinya CR: Cationic liposome-nucleic acid complexes for gene delivery and silencing: Pathways and mechanisms for plasmid DNA and siRNA. Top Curr Chem. 296:191–226. 2010. View Article : Google Scholar : PubMed/NCBI | |
Lin Q, Chen J, Zhang Z and Zheng G: Lipid-based nanoparticles in the systemic delivery of siRNA. Nanomedicine. 9:105–120. 2014. View Article : Google Scholar : PubMed/NCBI | |
van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, et al: Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 18:1386–1396. 2017. View Article : Google Scholar : PubMed/NCBI | |
Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, et al: Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 122:1630–1637. 2020. View Article : Google Scholar : PubMed/NCBI | |
Anselmo AC and Mitragotri S: Nanoparticles in the clinic: An update. Bioeng Transl Med. 4:e101432019. View Article : Google Scholar : PubMed/NCBI | |
Qattan A: Gene Silencing Agents in Breast Cancer. Modulating Gene Expression-Abridging the RNAi and CRISPR-Cas9 Technologies. Singh A W..Khan M: Intech Open; 2019, View Article : Google Scholar | |
Stratton MR, Campbell PJ and Futreal PA: The cancer genome. Nature. 458:719–724. 2009. View Article : Google Scholar : PubMed/NCBI | |
Pedroso de Lima MC, Simões S, Pires P, Faneca H and Düzgüneş N: Cationic lipid-DNA complexes in gene delivery: From biophysics to biological applications. Adv Drug Deliv Rev. 47:277–294. 2001. View Article : Google Scholar : PubMed/NCBI | |
Meraz IM, Savage DJ, Segura-Ibarra V, Li J, Rhudy J, Gu J and Serda RE: Adjuvant cationic liposomes presenting MPL and IL-12 induce cell death, suppress tumor growth, and alter the cellular phenotype of tumors in a murine model of breast cancer. Mol Pharm. 11:3484–3491. 2014. View Article : Google Scholar : PubMed/NCBI | |
Yu S, Bi X, Yang L, Wu S, Yu Y, Jiang B, Zhang A, Lan K and Duan S: Co-delivery of paclitaxel and PLK1-targeted siRNA using aptamer-functionalized cationic liposome for synergistic anti-breast cancer effects in vivo. J Biomed Nanotechnol. 15:1135–1148. 2019. View Article : Google Scholar : PubMed/NCBI | |
Wang W, Shao A, Zhang N, Fang J, Ruan JJ and Ruan BH: Cationic Polymethacrylate-modified liposomes significantly enhanced doxorubicin delivery and antitumor activity. Sci Rep. 7:430362017. View Article : Google Scholar : PubMed/NCBI | |
Sun Y, Zhao Y, Zhao X, Lee RJ, Teng L and Zhou C: Enhancing the therapeutic delivery of oligonucleotides by chemical modification and nanoparticle encapsulation. Molecules. 22:17242017. View Article : Google Scholar | |
Angelini G, Pisani M, Mobbili G, Marini M and Gasbarri C: Neutral liposomes containing crown ether-lipids as potential DNA vectors. Biochim Biophys Acta. 1828:2506–2512. 2013. View Article : Google Scholar : PubMed/NCBI | |
Yan Y, Li XQ, Duan JL, Bao CJ, Cui YN, Su ZB, Xu JR, Luo Q, Chen M, Xie Y and Lu WL: Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene. Int J Nanomedicine. 14:3645–3667. 2019. View Article : Google Scholar : PubMed/NCBI | |
Lu YC, Ou-Yang FU, Hsieh CM, Chang KJ, Chen DR, Tu CW, Wang HC and Hou MF: Pegylated liposomal doxorubicin as adjuvant therapy for stage I–III operable breast cancer. In Vivo. 30:159–163. 2016.PubMed/NCBI | |
Xu D, Tian W and Shen H: Curcumin prevents induced drug resistance: A novel function? Chin J Cancer Res. 23:218–223. 2011. View Article : Google Scholar : PubMed/NCBI | |
Tang X, Bi H, Feng J and Cao J: Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacologica Sinica. 26:1009–1016. 2005. View Article : Google Scholar : PubMed/NCBI | |
Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE and Altman RB: Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenet Genomics. 21:440–446. 2011. View Article : Google Scholar : PubMed/NCBI | |
Zhou S, Li J, Xu H, Zhang S, Chen X, Chen W, Yang S, Zhong S, Zhao J and Tang J: Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression. Gene. 622:1–12. 2017. View Article : Google Scholar : PubMed/NCBI | |
Golkar N, Samani SM and Tamaddon AM: Data on cell growth inhibition induced by anti-VEGF siRNA delivered by Stealth liposomes incorporating G2 PAMAM-cholesterol versus Metafectene® as a function of exposure time and siRNA concentration. Data Brief. 8:1018–1023. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chen J, Sun X, Shao R, Xu Y, Gao J and Liang W: VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer. Int J Nanomedicine. 12:6075–6088. 2017. View Article : Google Scholar : PubMed/NCBI | |
Leung AK, Tam YY and Cullis PR: Lipid Nanoparticles for short interfering RNA delivery. Adv Genet. 88:71–110. 2014. View Article : Google Scholar : PubMed/NCBI | |
Fernandez-Piñeiro I, Badiola I and Sanchez A: Nanocarriers for microRNA delivery in cancer medicine. Biotechnol Adv. 35:350–360. 2017. View Article : Google Scholar : PubMed/NCBI | |
Pandey H, Rani R and Agarwal V: Liposome and their applications in cancer therapy. Brazilian Arch Biol Technol. 592016.http://dx.doi.org/10.1590/1678-4324-2016150477. | |
Liu HM, Zhang YF, Xie YD, Cai YF, Li BY, Li W, Zeng LY, Li YL and Yu RT: Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy. Int J Nanomedicine. 12:1065–1083. 2017. View Article : Google Scholar : PubMed/NCBI | |
Modi S, Xiang TX and Anderson BD: Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions. J Control Release. 162:330–339. 2012. View Article : Google Scholar : PubMed/NCBI | |
Fenske DB, Chonn A and Cullis PR: Liposomal nanomedicines: An emerging field. Toxicol Pathol. 36:21–29. 2008. View Article : Google Scholar : PubMed/NCBI | |
Johnston MJ, Semple SC, Klimuk SK, Edwards K, Eisenhardt ML, Leng EC, Karlsson G, Yanko D and Cullis PR: Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta. 1758:55–64. 2006. View Article : Google Scholar : PubMed/NCBI | |
Lujan H, Griffin WC, Taube JH and Sayes CM: Synthesis and characterization of nanometer-sized liposomes for encapsulation and microRNA transfer to breast cancer cells. Int J Nanomedicine. 14:5159–5173. 2019. View Article : Google Scholar : PubMed/NCBI | |
de Antonellis P, Liguori L, Falanga A, Carotenuto M, Ferrucci V, Andolfo I, Marinaro F, Scognamiglio I, Virgilio A, De Rosa G, et al: MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines. Naunyn Schmiedebergs Arch Pharmacol. 386:287–302. 2013. View Article : Google Scholar : PubMed/NCBI | |
Samanta S, Rajasingh S, Drosos N, Zhou Z, Dawn B and Rajasingh J: Exosomes: New molecular targets of diseases. Acta pharmacologica Sinica. 39:501–513. 2018. View Article : Google Scholar : PubMed/NCBI | |
Bhome R, Del Vecchio F, Lee GH, Bullock MD, Primrose JN, Sayan AE and Mirnezami AH: Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer. Cancer Lett. 420:228–235. 2018. View Article : Google Scholar : PubMed/NCBI | |
Zhang J, Li S, Li L, Li M, Guo C, Yao J and Mi S: Exosome and exosomal microRNA: Trafficking, sorting, and function. Genomics Proteomics Bioinformatics. 13:17–24. 2015. View Article : Google Scholar : PubMed/NCBI | |
Xin Y, Wang X, Meng K, Ni C, Lv Z and Guan D: Identification of exosomal miR-455-5p and miR-1255a as therapeutic targets for breast cancer. Biosci Rep. 40:BSR201903032020. View Article : Google Scholar : PubMed/NCBI | |
Harris DA, Patel SH, Gucek M, Hendrix A, Westbroek W and Taraska JW: Exosomes released from breast cancer carcinomas stimulate cell movement. PLoS One. 10:e01174952015. View Article : Google Scholar : PubMed/NCBI | |
Lin R, Wang S and Zhao RC: Exosomes from human adipose-derived mesenchymal stem cells promote migration through Wnt signaling pathway in a breast cancer cell model. Mol Cell Biochem. 383:13–20. 2013. View Article : Google Scholar : PubMed/NCBI | |
Wu CY, Du SL, Zhang J, Liang AL and Liu YJ: Exosomes and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment. Cancer Gene Ther. 24:6–12. 2017. View Article : Google Scholar : PubMed/NCBI | |
Taylor DD and Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 110:13–21. 2008. View Article : Google Scholar : PubMed/NCBI | |
Silva J, Garcia V, Zaballos A, Provencio M, Lombardía L, Almonacid L, García JM, Domínguez G, Peña C, Diaz R, et al: Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J. 37:617–623. 2011. View Article : Google Scholar : PubMed/NCBI | |
Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD and Kloecker GH: Exosomal MicroRNA: A diagnostic marker for lung cancer. Clinical Lung Cancer. 10:42–46. 2009. View Article : Google Scholar : PubMed/NCBI | |
Wu H, Wang Q, Zhong H, Li L, Zhang Q, Huang Q and Yu Z: Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next-generation sequencing. Oncol Rep. 43:240–250. 2019.PubMed/NCBI | |
Allen TM, Hansen C, Martin F, Redemann C and Yau-Young A: Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta. 1066:29–36. 1991. View Article : Google Scholar : PubMed/NCBI | |
Klibanov AL, Maruyama K, Torchilin VP and Huang L: Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:235–237. 1990. View Article : Google Scholar : PubMed/NCBI | |
Senior J, Delgado C, Fisher D, Tilcock C and Gregoriadis G: Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: Studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta. 1062:77–82. 1991. View Article : Google Scholar : PubMed/NCBI | |
Immordino ML, Dosio F and Cattel L: Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 1:297–315. 2006.PubMed/NCBI | |
Caliceti P: Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Delivery Rev. 55:1261–1277. 2003. View Article : Google Scholar | |
Barenholz Y: Doxil®−The first FDA-approved Nano-drug: Lessons learned. J Control Release. 160:117–134. 2012. View Article : Google Scholar : PubMed/NCBI | |
Vakhshiteh F, Khabazian E, Atyabi F, Ostad SN, Madjd Z and Dinarvand R: Peptide-conjugated liposomes for targeted miR-34a delivery to suppress breast cancer and cancer stem-like population. J Drug Deliv Sci Technol. 57:1016872020. View Article : Google Scholar | |
Amstad E, Kohlbrecher J, Müller E, Schweizer T, Textor M and Reimhult E: Triggered release from liposomes through magnetic actuation of iron oxide nanoparticle containing membranes. Nano Lett. 11:1664–1670. 2011. View Article : Google Scholar : PubMed/NCBI | |
Nahire R, Hossain R, Patel R, Paul S, Meghnani V, Ambre AH, Gange KN, Katti KS, Leclerc E, Srivastava DK, et al: pH-Triggered echogenicity and contents release from liposomes. Mol Pharm. 11:4059–4068. 2014. View Article : Google Scholar : PubMed/NCBI | |
Khan DR, Webb MN, Cadotte TH and Gavette MN: Use of targeted liposome-based chemotherapeutics to treat breast cancer. Breast Cancer (Auckl). 9 (Suppl 2):S1–S5. 2015. | |
Ta T and Porter TM: Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. J Control Release. 169:112–125. 2013. View Article : Google Scholar : PubMed/NCBI | |
Elegbede AI, Banerjee J, Hanson AJ, Tobwala S, Ganguli B, Wang R, Lu X, Srivastava DK and Mallik S: Mechanistic studies of the triggered release of liposomal contents by matrix metalloproteinase-9. J Am Chem Soc. 130:10633–10642. 2008. View Article : Google Scholar : PubMed/NCBI | |
Brown S and Khan DR: The treatment of breast cancer using liposome technology. J Drug Deliv. 2012:2129652012. View Article : Google Scholar : PubMed/NCBI | |
Sneider A, Jadia R, Piel B, VanDyke D, Tsiros C and Rai P: Engineering remotely triggered liposomes to target triple negative breast cancer. Oncomedicine. 2:1–13. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yang G, Liu Z, Li Y, Hou Y, Fei X, Su C, Wang S, Zhuang Z and Guo Z: Facile synthesis of black phosphorus-Au nanocomposites for enhanced photothermal cancer therapy and surface-enhanced Raman scattering analysis. Biomater Sci. 5:2048–2055. 2017. View Article : Google Scholar : PubMed/NCBI | |
Qiu M, Ren WX, Jeong T, Won M, Park GY, Sang DK, Liu LP, Zhang H and Kim JS: Omnipotent phosphorene: A next-generation, two-dimensional nanoplatform for multidisciplinary biomedical applications. Chem Soc Rev. 47:5588–5601. 2018. View Article : Google Scholar : PubMed/NCBI | |
Sun S, Xu Y, Fu P, Chen M, Sun S, Zhao R, Wang J, Liang X and Wang S: Ultrasound-targeted photodynamic and gene dual therapy for effectively inhibiting triple negative breast cancer by cationic porphyrin lipid microbubbles loaded with HIF1α-siRNA. Nanoscale. 10:19945–19956. 2018. View Article : Google Scholar : PubMed/NCBI | |
Tang J, Li B, Howard CB, Mahler SM, Thurecht KJ, Wu Y, Huang L and Xu ZP: Multifunctional lipid-coated calcium phosphate nanoplatforms for complete inhibition of large triple negative breast cancer via targeted combined therapy. Biomaterials. 216:1192322019. View Article : Google Scholar : PubMed/NCBI | |
Ghasemiyeh P and Mohammadi-Samani S: Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages. Res Pharma Sci. 13:288–303. 2018. View Article : Google Scholar |